Russian Heart Failure Journal 2008year Levels of serotonin in blood and platelets of patients with CHF

To access this material please log in or register

Register Authorize

Levels of serotonin in blood and platelets of patients with CHF

Nigmatullina R. R., Kirillova V. V., Dzhordzhikiya P. K, Kudrin V. S., Klodt P. M.



Urgency. The serotonin system plays an important role in pathogenesis of cardiovascular diseases. However the role of serotonin (5-НТ) in development and progression of CHF is not studied. Aim. To measure plasma and platelet levels of 5-НТ and its major metabolite 5-hydroxyindoleacetic acid (5-HIAA) in patients with CHF and to evaluate the relationship of these levels with severity of morpho-functional changes in the myocardium. Materials and methods. Concentrations of 5-HT in plasma and platelets and 5-hydroxyindoleacetic acid (5-HIAA) in plasma were measured using the method of high-performance liquid chromatography with electrochemical detection in 23 CHF patients with different morpho-functional alterations of the myocardium. Results. All patients with CHF had increased 5-HT concentrations in plasma and platelets. The highest platelet levels of 5-HT were found in patients with isolated LV diastolic dysfunction (DD). Concentration of the 5-HT metabolite 5-HIAA was increased in patients with DD and LV hypertrophy and in patients with DD and systolic dysfunction. Therefore synthesis and metabolism of 5-HT are changed in CHF in relation to morpho-functional alterations of the myocardium.
  1. Brum PC, Rolim NP, Bacurau AV, Medeiros A.. Neurohumoral activation in heart failure: the role of adrenergic receptors. An Acad Bras Cienc. 2006;78(3):485-503.
  2. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415(6868):206-212.
  3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
  4. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;271(18):1450-1456.
  5. Vanhoutte P.M. Cardiovascular effects of serotonin. J Cardiovasc Pharmacol. 1987;10(Suppl 3):S8-11.
  6. Côté F, Fligny C, Fromes Y et al. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med. 2004;10(5):232-238.
  7. Puri VK, Verma M, Saxena AK, Shanker K. Platelet serotonergic mechanisms in ischaemic heart disease. Thromb Res. 1990;57(3):445-451.
  8. Cooper JR, BloomFE, Roth RH. Serotonin (5-hydroxytryptamine), histamine and adenosine. In: The Biochemical Basis of Neuropharmacology. Oxford University Press, New York 2003; 271-320.
  9. Tyce GM. Origin and metabolism of serotonin. J Cardiovasc Pharmacol. 1990;16(Suppl 3):51-57.
  10. Willerson JT. Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products. Tex Heart Inst J. 1995;22(1):13-19.
  11. Pakala R, Benedict CR. Effect of serotonin and thromboxane A2 on endothelial cell proliferation: effect of specific receptor antagonists. J Lab Clin Med. 1998;131(6):527-537.
  12. Suhara T, Sudo Y, Yoshida K et al. Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet. 1998;351(9099): 332-335.
  13. Gillis CN, Pitt BR. The fate of circulating amines within the pulmonary circulation. Annu Rev Physiol. 1982;44:269-281.
  14. Fumeron F, Betoulle D, Nicaud V et al. Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Temoins de I’Infarctus du Myocarde (ECTIM). Circulation. 2002;105(25):2943-2945.
  15. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108(1):32-36.
  16. Мустафин А.А., Нигматуллина Р.Р., Миролюбов Л.М. и др. Роль серотонинэргической системы в формировании легочной артериальной гипертензии у детей с врожденными пороками сердца. Клиническая физиология кровообращенияю 2007;2:42-46.
  17. Ashton JH, Benedict CR, Fitzgerald C et al. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation. 1986;73(3):572-578.
  18. Golino P, Piscione F, Willerson JT et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med. 1991;324(10):641-648.
  19. Noble M, Drake-Holland AJ. Evidence for a role of serotonin in inhibition of coronary arterial thrombosis in dog and man. Clin Physiol Biochem. 1991; 8(Suppl 3):50-55.
  20. Herving TA, Farstad M. Human blood platelet serotonin studies in vitro: endogenous serotonin may stimulate thrombin-induced serotonin release in stored platelets. Platelets 1996;7(1-2):53-57.
  21. Farstad M. The role of blood platelets in coronary atherosclerosis and thrombosis. Scand J Clin Lab Invest. 1998;58(1):1-10.
  22. Greenberg BD, Tolliver TJ, Huang SJ et al. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet. 1999;88(1):83-87.
  23. Fumeron F, Betoulle D, Nicaud V et al. Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Témoins de l’Infarctus du Myocarde (ECTIM). Circulation. 2002;105(25):2943-2945.
  24. Whyte EM, Pollock BG, Wagner WR et al. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geratic depression. Am J Psychiatry. 2001;158(12):2074-2076.
  25. Tyrer SP, Marshall EF, Griffiths HW. The relationship between respons to fluoxetine, plasma drug levels, imipramine binding to platelet membranes and whole-blood 5-HT. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(5):797-805.

To access this material please log in or register

Register Authorize
Ru En